 HOUSTON, Texas and VANCOUVER, Canada, April 10, 2021 PRNewswire -- ESSA Pharma Inc. ESSA or the Company Nasdaq: EPIX, a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSAs lead product candidate, EPI-7386, at the 2021 American Association of Cancer Research AACR Annual Meeting, which is taking place virtually April 10-15, 2021. EPI-7386 is an investigational, highly selective, oral, small molecule inhibitor of the N-terminal domain of the androgen receptor, which exhibits high potency, low metabolism and on-target specificity. 